本文へ移動
cccskills
無料GitHub で公開

enda-pediatric-hc-bsa-dosing

Recommends initiating hydrocortisone replacement at a total starting dose of 8 mg/m2 body surface area per day, given in three or four divided doses, for children with confirmed primary adrenal insufficiency (PAI). Use when starting glucocorticoid therapy in pediatric PAI patients, adjusting the dose according to individual clinical response, growth, and need for stress coverage.

インストール方法を見る

含まれるファイル(1)

  • SKILL.md2.9 KB

SKILL.md(原文)

インストールする前に、エージェントに与えられる指示の中身を確認できます。

Treat Children with PAI Using Hydrocortisone with BSA-Based Dosing

STEP 1 — Gather Information

Confirm PAI diagnosis with low cortisol response to ACTH stimulation test and elevated ACTH; assess for aldosterone deficiency (renin, aldosterone); measure weight and height to calculate body surface area (BSA); review growth parameters, weight, blood pressure, and signs of glucocorticoid over- or under-replacement.

STEP 2 — Rule In / Rule Out

Is PAI biochemically confirmed (subnormal cortisol peak after 250 µg ACTH with elevated ACTH)?

  • Yes → proceed to Step 3.
  • No → consider secondary adrenal insufficiency, transient causes, or non‑adrenal etiologies; do not initiate glucocorticoid replacement pending further evaluation.

STEP 3 — Classify or Stratify

Determine if the child has concomitant aldosterone deficiency (elevated plasma renin with low aldosterone) requiring fludrocortisone replacement; if yes, plan mineralocorticoid therapy in addition to glucocorticoid dosing.

STEP 4 — Decide

Start hydrocortisone at 8 mg/m2/day divided into three or four doses (largest dose upon waking, subsequent doses spaced 4–6 hours apart, last dose not later than 4–6 hours before bedtime); adjust dose based on clinical wellbeing, growth velocity, blood pressure, and signs of over- (weight gain, Cushingoid features, hypertension) or under-replacement (fatigue, hypotension, hyperpigmentation, poor growth).

Clinical Guardrails / Mimics / Pitfalls

Do not use synthetic long‑acting glucocorticoids (e.g., dexamethasone, prednisolone) as first‑line in children; avoid dosing based solely on weight without BSA calculation; do not adjust dose based on plasma ACTH levels; avoid exceeding 20 mg/m2/day in infants or 15–17 mg/m2/day in adolescents without clear clinical indication; ensure patient/family education on stress dosing and emergency injection kit.

Concrete Clinical Example

A 4‑year‑old boy (weight 16 kg, height 100 cm, BSA ≈0.78 m2) with newly diagnosed PAI (low cortisol after 250 µg ACTH, high ACTH) and normal aldosterone. Starting hydrocortisone dose = 8 mg/m2/day × 0.78 m2 ≈ 6.2 mg/day, given as 2 mg at 08:00, 2 mg at 12:00, and 2.2 mg at 16:00. After two weeks, weight gain is appropriate and no Cushingoid signs; dose maintained.

Source: Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, DOI:10.1210/jc.2015-1710

レビュー

まだレビューはありません。使ってみた感想をお寄せください。

同じリポジトリのスキル

概要と使いどころ

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

dromlakhani のスキルをすべて見る

このスキルの問題を報告する